Magnesium Citrate

Summary

Magnesium Citrate (CHEMBL3989480) is an approved small-molecule laxative (ATC B05CB03); indicated across 6 conditions including constipation disorder and hypertensive disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: B05CB03 (+2 more)
• Indications: 6 conditions
• Clinical trials: 25
• Chemistry: 451.12 Da · C12H10Mg3O14

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3989480
Name	Magnesium Citrate
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	6099959
ChEBI	CHEBI:131391
ATC	B05CB03, A12CC04, A06AD19
Molecular formula	C12H10Mg3O14
Molecular weight	451.12
InChIKey	PLSARIKBYIPYPF-UHFFFAOYSA-H

SMILES: C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.[Mg+2].[Mg+2].[Mg+2]

IUPAC name: trimagnesium bis(2-hydroxypropane-1,2,3-tricarboxylate)

ChEBI definition: A magnesium salt composed of magnesium and citrate ions in a 3:2 ratio.

Pharmacological roles (ChEBI): laxative.

Also known as: Citramag, Citric acid, magnesium salt (2:3), Mag cit, Mag diasporal 300, Magcit, Magnesium citrate, NSC-83517, MAGNESIUM CITRATE

Patent coverage: 4,951 distinct patent families (13,908 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
constipation disorder	4	MONDO:0002203	HP:0002019
hypertensive disorder	2	MONDO:0005044	EFO:0000537
diabetic kidney disease	2	MONDO:0005016	EFO:0000401
severe acute respiratory syndrome	1	MONDO:0005091	MONDO:0100096
essential hypertension	1	MONDO:0001134	MONDO:0001134

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 25.

Phase distribution

Phase	Trials
Not specified	11
PHASE4	6
PHASE3	4
PHASE2	3
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03088852	PHASE4	RECRUITING	Magnesium Deficiency In Patients Hospitalized in Internal Medicine Wards
NCT00994006	PHASE4	COMPLETED	The Absorption of Magnesium Oxide Compared to Citrate in Healthy Subjects
NCT01909219	PHASE4	COMPLETED	PMC Split Preparation for Colon Cleansing
NCT02956057	PHASE4	COMPLETED	Polyethylene Glycol Versus Low Volume Solutions Prior to Colonoscopy
NCT03698474	PHASE4	COMPLETED	Comparison of Different Low Volume Solutions Prior to Colonoscopy
NCT04598880	PHASE4	COMPLETED	Comparison of 1 Liter PEG With Ascorbate and Sodium Picosulfate / Magnesium Citrate for High Quality Colon Cleansing
NCT05018221	PHASE3	RECRUITING	Better Evidence and Translation for Calciphylaxis
NCT00275184	PHASE3	UNKNOWN	Bowel Preparation and Prokinetics in Capsule Endoscopy
NCT02032186	PHASE3	COMPLETED	A Randomized Clinical Trial of Oral Magnesium Supplementation in Pregnancy
NCT04021381	PHASE3	UNKNOWN	Citrate Salts for Stone-free Result After Flexible Ureterorenoscopy for Inferior Calyx Calculi
NCT02822222	PHASE1/PHASE2	COMPLETED	Safety Study of RMJH-111b to Treat Essential Hypertension
NCT03824379	PHASE2	COMPLETED	Magnesium Supplementation in Diabetic Nephropathy
NCT04132427	PHASE2	COMPLETED	MTT for Children With Both Pitt Hopkins Syndrome and Gastrointestinal Disorders
NCT06321796	PHASE2	UNKNOWN	Microbiota Transfer Therapy for Children and Adults With Both Pitt Hopkins Syndrome and Gastrointestinal Disorders
NCT07309640	Not specified	NOT_YET_RECRUITING	The Effects of Magnesium (Mg) Supplement and Alternate Maxillary Expansion and Constriction (Alt-RAMEC) in Patient With Transverse Maxillary Deficiency (TMD)
NCT01510665	Not specified	COMPLETED	Magnesium Supplementation in the Second Trimester of Pregnancy to Overweight and Obese Individuals
NCT02235805	Not specified	COMPLETED	Magnesium and Vascular Stiffness
NCT02690012	Not specified	COMPLETED	Feasibility of Using an Integrated Consent Model to Compare Two Standard of Care Regimens for the Management of Hypomagnesemia From Anti-Cancer Therapies
NCT03002545	Not specified	COMPLETED	Magnesium Supplementation in Type II Diabetes
NCT03247595	Not specified	COMPLETED	Testing How Well Magnesium Citrate Capsules Work as Preparation for a Colonoscopy
NCT03632590	Not specified	UNKNOWN	Magnesium and Vascular Stiffness
NCT03716609	Not specified	COMPLETED	Effects of Magnesium Supplementation on Hemodynamic Parameters and Cognitive Function
NCT04462796	Not specified	UNKNOWN	The Effect of Magnesium Citrate Supplementation in Restless Legs Syndrome (RLS)
NCT04930237	Not specified	WITHDRAWN	RELISTOR’s Effects on Opioid-Induced Constipation
NCT05597150	Not specified	COMPLETED	The Exploration of the Regulatory Effect of Magnesium on Intestinal Flora in Healthy Adults

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).